CJC-1295 / Ipamorelin

01 · What is it?

The identity comes first.

This label combines CJC-1295, Ipamorelin. It is not a single molecule with one validated mechanism. Evidence for separate ingredients does not establish the effects of the exact mixture.

Scientific classification: Combination formula; multiple distinct peptide identities

For example. Several messages sent at once can overlap, interfere or change each other’s timing. More ingredients do not automatically mean a stronger result.

02 · How does it work?

The signal, explained.

The ingredients may act at different targets, but their combined behavior is not established. Separate mechanisms cannot be added together to predict a mixture’s human effects.

The key research focus is Growth-hormone-releasing hormone receptor (GHRHR) / Ghrelin receptor (GHSR-1a). A target describes where an interaction may occur; it does not by itself establish a benefit.

03 · What happens after the signal?

Follow the downstream effects.

The proposed downstream events belong to the individual ingredients. Their timing, exposure and interactions in this exact mixture are not established. No claim of additive benefit or synergy follows from putting those pathways side by side.

To connect this mechanism to a real-world outcome, researchers need to establish exposure at the target, measure the response and test whether the change matters in a controlled human study.

04 · What is it commonly researched for?

The questions researchers are asking.

Research interpretation requires the exact sequences, composition and mixture-specific studies. Internet “stack” names cannot substitute for controlled research.

These are areas of investigation, not promises about a Maison product.

05 · Body systems involved

Where the biology connects.

Pituitary

Releases hormones in response to hypothalamic and receptor signals.

Liver

A central site of nutrient handling, metabolic enzymes and selected downstream hormone responses.

Digestive tract

Relevant to secretion, motility, epithelial transport or gut–brain signaling.

06 · Receptor / target profile

The molecular reference card.

Primary receptor or target

Growth-hormone-releasing hormone receptor (GHRHR) / Ghrelin receptor (GHSR-1a)

Secondary interactions

No additional primary target established for the research claim discussed.

Where it is found

Potential ingredient targets only; no combined target profile has been clinically validated.

Activation, inhibition or interaction

CJC-1295: GHRHR agonism in pituitary somatotrophs increases cAMP signaling and growth-hormone secretion. The DAC modification enables albumin binding and prolonged exposure in the studied molecule. Ipamorelin: GHSR-1a agonism can activate Gq/PLC/IP3/calcium signaling and stimulate pituitary growth-hormone release. Effects depend on tissue and endocrine context.

Important downstream pathways

The proposed downstream events belong to the individual ingredients. Their timing, exposure and interactions in this exact mixture are not established. No claim of additive benefit or synergy follows from putting those pathways side by side.

07 · Evidence quality

What carries weight—and what does not.

A familiar mechanism, a patent, a testimonial or a trial registration alone cannot establish human efficacy or product quality.

08 · Who is studying it?

Follow the original research.

No current sponsor-led clinical development program was verified for this exact research identity. This does not prove that no study exists; consult current records and distinguish related molecules.

Regulatory context: Research combination. An approved use for any one ingredient does not authorize this blend.

Registry links may include related compounds or historical studies. Read the exact intervention, sponsor, phase and latest update date. Recruitment status is specific to each trial.

09 · Research terminology

A small glossary for this page.

Explore the complete foundations glossary

10 · Research status & limitations

Keep the boundaries visible.

Research combination. An approved use for any one ingredient does not authorize this blend.

Combination-specific safety, stability, interactions and human outcomes are not established.

The main evidence category here is unknown or insufficient evidence. The exact molecule, formulation, study population and endpoint matter. Scientific evidence changes; this page is a dated educational summary, not continuous trial monitoring.